Viralytics Limited (ASX: VLA, OTC: VRACY)is pleased to advise that ROTH Capital Partners has issued an update to its Viralytics coverage following the recent Oncolytic Virus Conference in Boston and an Investor Teleconference in which Dr Robert Andtbacka presented the final results from the CALM melanoma trial.

A copy of the ROTH Update, dated 16 June, is available on our website.

Enquiries

Dr Malcolm McColl
02 9988 4000
Website: www.viralytics.com
About Viralytics Ltd:
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK's preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has a number of clinical trials in progress, including:
  • A Phase 2 clinical trial of intratumourally administered CAVATAK in the treatment of Late-Stage Melanoma (the CALM study), underway in the U.S.
  • An extension to the CALM study focused on a deeper understanding of the immunotherapeutic activity of CAVATAK
  • A Phase1/2 clinical trial of intravenously delivered CAVATAK in patients with melanoma, prostate, lung or metastatic bladder cancers, referred to as the STORM (Systemic Treatment of Resistant Malignancies) study, underway in the UK
  • A Phase 1 clinical trial of CAVATAK in bladder cancer, known as the CANON (CAVATAK for treatment of NON-muscle invasive bladder cancer) study, underway in the UK
  • A Phase 1b clinical trial of CAVATAK in combination with YERVOY® (ipilimumab) in late-stage melanoma patients.
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.
Copyright © *2015* *Viralytics Limited*, All rights reserved.

Our mailing address is:
Viralytics Limited
Suite 305, Level 3
66 Hunter Street
Sydney NSW 2000
T: +61 2 9988 4000
F: +61 2 8068 6038
E: Viralytics@viralytics.com
distributed by